Short answer
ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Investor Presentation supports upcoming investor and analyst meetings, including Jefferies Global Healthcare Conference beginning June 2, 2026.
ARVINAS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor Presentation supports upcoming investor and analyst meetings, including Jefferies Global Healthcare Conference beginning June 2, 2026
- Presentation content may be updated through future Form 8-K filings or other company disclosures
- Exhibit 99.1 contains the substantive investor materials relevant to Arvinas’ current messaging and outlook
Item 8.01 · Other Events
- ARV-806 portfolio deprioritization limits Arvinas’ internal development beyond the ongoing Phase 1 monotherapy trial
- Phase 1 dose-escalation trial completion and clinical data expected in 2026
- Additional ARV-806 trials contingent on securing an out-licensing agreement
- Cash, cash equivalents and marketable securities expected to fund operations into the second half of 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARVINAS, INC. 8-K filings
Get the next ARVN 8-K as it lands
Follow ARVN for push alerts, or ask the research agent what this filing means.